2024
Patterns of CNS Failures in Relapse/Refractory Large B-Cell Lymphoma (LBCL) Patients with Secondary CNS Disease Following Chimeric Antigen Receptor T-Cell (CAR T) Therapy
Nakashima J, Khatri V, Cruz-Chamorro R, Zhou J, Patra P, Gaballa S, Khimani F, Mirza S, Shah B, Saeed H, Chavez J, Locke F, Nishihori T, Liu H, Dong N, Lazaryan A, Robinson T, Freeman C, Jain M, Figura N. Patterns of CNS Failures in Relapse/Refractory Large B-Cell Lymphoma (LBCL) Patients with Secondary CNS Disease Following Chimeric Antigen Receptor T-Cell (CAR T) Therapy. International Journal Of Radiation Oncology • Biology • Physics 2024, 120: e646-e647. DOI: 10.1016/j.ijrobp.2024.07.1421.Peer-Reviewed Original ResearchLarge B-cell lymphomaSecondary CNS lymphomaB-cell lymphomaCNS failureCNS recurrenceCNS diseaseCNS lymphomaCAR-TOverall survivalBridging therapyCNS diagnosisRelapsed/refractory large B-cell lymphomaChimeric antigen receptor T cellsCAR-T cell trialsPattern of failure analysisCAR-T cell therapyMedian age of patientsClinical outcomes of patientsCNS-only progressionSystemic disease recurrenceT-cell therapyCAR-T therapyCytokine-release syndromePatterns of recurrenceKaplan-Meier methodBSLM-03 BRANCHED-CHAIN KETO ACIDS PROMOTE AN IMMUNE-SUPPRESSIVE AND NEURODEGENERATIVE MICROENVIRONMENT IN LEPTOMENINGEAL DISEASE
Khaled M, Ren Y, Kundalia R, Alhaddad H, Chen Z, Wallace G, Evernden B, Ospina O, Hall M, Liu M, Darville L, Izumi V, Chen Y, Pilon-Thomas S, Stewart P, Koomen J, Corallo S, Jain M, Robinson T, Locke F, Forsyth P, Smalley I. BSLM-03 BRANCHED-CHAIN KETO ACIDS PROMOTE AN IMMUNE-SUPPRESSIVE AND NEURODEGENERATIVE MICROENVIRONMENT IN LEPTOMENINGEAL DISEASE. Neuro-Oncology Advances 2024, 6: i5-i5. PMCID: PMC11296858, DOI: 10.1093/noajnl/vdae090.014.Peer-Reviewed Original ResearchChimeric antigen receptorLeptomeningeal diseaseBranched-chain keto acidsSodium phenylbutyrateCerebrospinal fluidSurvival outcomesT cellsBreast cancerEfficacy of CAR T-cell therapyAnti-tumor immune environmentCAR-T cell therapyMurine model of breast cancerResponse to immune therapyModel of breast cancerFunction of T lymphocytesT-cell therapyDysfunctional T cellsComprehensive multi-omics analysisPoor survival outcomesCerebrospinal fluid of patientsAnalysis of cerebrospinal fluidPreclinical rationaleImmune therapyImmune environmentNeurological deterioration
2023
Bridging Radiotherapy Prior to Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphomas: An ILROG Multi-Institutional Study
Yegya-Raman N, Wright C, Ladbury C, Chew J, Zhang S, Sun S, Burke S, Baron J, Sim A, LaRiviere M, Yang J, Robinson T, Tseng Y, Terezakis S, Braunstein S, Dandapani S, Schuster S, Chong E, Plastaras J, Figura N. Bridging Radiotherapy Prior to Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphomas: An ILROG Multi-Institutional Study. International Journal Of Radiation Oncology • Biology • Physics 2023, 117: s50-s51. DOI: 10.1016/j.ijrobp.2023.06.333.Peer-Reviewed Original ResearchImmune effector cell-associated neurotoxicity syndromeProgression-free survivalCytokine release syndromeB-cell lymphomaChimeric antigen receptor T-cell therapySuperior progression-free survivalLarge B-cell lymphomaCAR-T infusionT-cell therapyMulti-institutional studyOverall survivalCTCAE v5.0T infusionTisa-celCAR TRefractory aggressive B-cell lymphomasStage III/IV diseaseT-cell/histiocyte-rich large B-cell lymphomaFavorable progression-free survivalCentral nervous system involvementDiffuse large B-cell lymphomaAggressive B-cell lymphomasPrimary mediastinal B-cell lymphomaMediastinal B-cell lymphomaNervous system involvement
2022
Radiation therapy prior to CAR T-cell therapy in lymphoma: impact on patient outcomes
Figura N, Sim A, Jain M, Chavez J, Robinson T. Radiation therapy prior to CAR T-cell therapy in lymphoma: impact on patient outcomes. Expert Review Of Hematology 2022, 15: 1023-1030. PMID: 36369950, DOI: 10.1080/17474086.2022.2147919.Peer-Reviewed Original ResearchConceptsCAR T-cell therapyT-cell therapySalvage radiotherapyPatient outcomesAnti-CD19 chimeric antigen receptor (CAR) T-cell therapyChimeric antigen receptor T-cell therapyLarge B-cell lymphomaCurrent retrospective dataHigh tumor burdenClinical risk factorsAblative radiation dosesHypothesis-driven clinical trialsB-cell lymphomaMost patientsR DLBCLLocal recurrenceTumor burdenClinical evidenceRisk factorsTreatment paradigmClinical trialsTreatment outcomesRadiation therapyElevated riskPatientsMulti-Institutional Review of Bridging Radiotherapy Prior to Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphomas
Yegya-Raman N, Wright C, Figura N, Zhang S, Chew J, Burke S, Sim A, LaRiviere M, Baron J, Sinha S, Yang J, Robinson T, Jain M, Maity A, Paydar I, Tseng Y, Braunstein S, Schuster S, Chong E, Plastaras J. Multi-Institutional Review of Bridging Radiotherapy Prior to Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphomas. Blood 2022, 140: 10900-10901. DOI: 10.1182/blood-2022-157540.Peer-Reviewed Original ResearchPatient-Level Disease Burden as a Predictor of In-Field Failures in Patients Undergoing Bridging Radiotherapy for CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Recurrent/Refractory Large B-Cell Lymphomas
Figura N, Sim A, Chavez J, Shah B, Khimani F, Lazaryan A, Davila M, Bachmeier C, Nishihori T, Liu H, Christopherson K, Kim S, Locke F, Jain M, Robinson T. Patient-Level Disease Burden as a Predictor of In-Field Failures in Patients Undergoing Bridging Radiotherapy for CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Recurrent/Refractory Large B-Cell Lymphomas. International Journal Of Radiation Oncology • Biology • Physics 2022, 114: s85. DOI: 10.1016/j.ijrobp.2022.07.491.Peer-Reviewed Original ResearchMedian metabolic tumor volumeT-cell therapyRefractory large B-cell lymphomaCAR T-cell therapyLarge B-cell lymphomaBRT patientsDisease burdenTotal disease burdenB-cell lymphomaField progressionRadiation therapyLocal controlClinical outcomesExact testChimeric antigen receptor T-cell therapyCAR T-cell infusionDistant-only failureDurable local controlLocal-only failureWorse disease burdenFuture prospective trialsT-cell infusionHigh-risk patientsKaplan-Meier methodLow disease burden
2021
In-Field Failures in Patients Undergoing Bridging Radiotherapy for CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Recurrent/Refractory Large B-Cell Lymphomas
Sim A, Figura N, Dohm A, Chavez J, Shah B, Khimani F, Lazaryan A, Davila M, Bachmeier C, Nishihori T, Liu H, Kim S, Locke F, Jain M, Robinson T. In-Field Failures in Patients Undergoing Bridging Radiotherapy for CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Recurrent/Refractory Large B-Cell Lymphomas. International Journal Of Radiation Oncology • Biology • Physics 2021, 111: s131. DOI: 10.1016/j.ijrobp.2021.07.297.Peer-Reviewed Original ResearchMetabolic tumor volumeRefractory large B-cell lymphomaCAR T-cell infusionLarge B-cell lymphomaT-cell infusionT-cell therapyB-cell lymphomaTreatment failureChimeric antigen receptor T-cell therapyField local control rateCAR T-cell therapyBaseline PET/CTLocal failureCAR-T infusionExperience disease progressionLower RT dosesDisease-free survivalLocal control rateMajority of patientsAdequate local controlCAR-T therapyPatterns of failurePET/CTMATERIAL/METHODSCommon regimensPO-1075 Bridging Radiotherapy prior to Brexucabtagene Autoleucel CAR T-Cell Therapy in Mantle Cell Lymphoma
Figura N, Sim A, Dahiya S, Lutfi F, Rapoport A, Mohindra P, Dohm A, Chavez J, Shah B, Khimani F, Lazaryan A, Davila M, Bachmeier C, Nishihori T, Liu H, Kim S, Locke F, Jain M, Robinson T. PO-1075 Bridging Radiotherapy prior to Brexucabtagene Autoleucel CAR T-Cell Therapy in Mantle Cell Lymphoma. Radiotherapy And Oncology 2021, 161: s894-s895. DOI: 10.1016/s0167-8140(21)07526-5.Peer-Reviewed Original Research